Component
Total International Prostate Symptom Score
Symptom score for lower urinary tract symptoms.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Tadalafil 5 mg once daily improved the total International Prostate Symptom Score by a mean difference of 2.3 points against placebo in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Experimental context and source evidence
- duration
- 12 weeks
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- 1500 men pooled from four international randomised placebo-controlled studies
- exposure
- Tadalafil 5 mg once daily against placebo
- limitations
- A pooled analysis rather than a single trial. Improvements were significant regardless of baseline symptom severity, age, recent alpha-blocker or PDE5 inhibitor use, total testosterone or predicted prostate volume, so no subgroup was identified in which the effect was absent, and the mechanism in this tissue is not established by the symptom score. PubMed records an erratum for this paper without a resolvable identifier, and the abstract itself carries an inline corrected marker, so it is not known whether the erratum altered these figures.
- organism
- 1500 men pooled from four international randomised placebo-controlled studies
- plain_language
- Tadalafil 5 mg once daily improved the total International Prostate Symptom Score by a mean difference of 2.3 points against placebo in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- primary_references
- Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (2013). https://pubmed.ncbi.nlm.nih.gov/23876588/ DOI: 10.1016/j.urology.2013.05.005
- route
- Oral
- tissue
- Lower urinary tract symptoms
Tadalafil: PDE5 occupancy, the cGMP route and three measured endpoints (2026-09-22) · lines 111–120
Original AI-assisted curation of seven primary studies resolved by PubMed title search, with every abstract read and all DOIs cross-checked against live PubMed metadata. Two references carry an unresolvable erratum and are recorded as corrected. Study-specific doses, effect sizes and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## tadalafil-lowers-prostate-symptom-score Tadalafil 5 mg once daily improved the total International Prostate Symptom Score by a mean difference of 2.3 points against placebo in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Model/species: 1500 men pooled from four international randomised placebo-controlled studies Tissue/system: Lower urinary tract symptoms Exposure: Tadalafil 5 mg once daily against placebo Route: Oral Duration: 12 weeks Limits: A pooled analysis rather than a single trial. Improvements were significant regardless of baseline symptom severity, age, recent alpha-blocker or PDE5 inhibitor use, total testosterone or predicted prostate volume, so no subgroup was identified in which the effect was absent, and the mechanism in this tissue is not established by the symptom score. PubMed records an erratum for this paper without a resolvable identifier, and the abstract itself carries an inline corrected marker, so it is not known whether the erratum altered these figures. Primary reference: Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia. (2013). https://pubmed.ncbi.nlm.nih.gov/23876588/ DOI: 10.1016/j.urology.2013.05.005 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.